DeviceConX®

Meet Lisa
Learn how GPS Cancer is transforming the way cancer is treated.

Meet Lisa
Learn how GPS Cancer is transforming the way cancer is treated.

Meet Lisa
Learn how GPS Cancer is transforming the way cancer is treated.

DeviceConX®

Nurse resources are valuable. Streamline rounding with automated vital signs collection.

Nurse resources are valuable. Streamline rounding with automated vital signs collection.

Nurse resources are valuable. Streamline rounding with automated vital signs collection.

VitalsConX

VitalsConX

VitalsConX

GPS Cancer
GPS Cancer

A unique, comprehensive molecular test enabling personalized cancer treatment.

“Our knowledge in the science of genomics, proteomics, and immunology has advanced at an unprecedented speed, making now the time for the rapid deployment of immunotherapy for the benefit of millions of cancer patients.”

Patrick Soon-Shiong, M.D., FRCS(C), FACS

“Our knowledge in the science of genomics, proteomics, and immunology has advanced at an unprecedented speed, making now the time for the rapid deployment of immunotherapy for the benefit of millions of cancer patients.”

Patrick Soon-Shiong, M.D., FRCS(C), FACS

Founder, Chief Executive Officer, and Chairman of the Board

Play

play video

play video

play video

Arrow
Arrow
Slider

Enabling Value Based Care through Precision Medicine

At NantHealth we leverage the latest advancements in precision medicine and software technology to enable true value based care. Our solutions are holistic and comprehensive, transforming the way illness is known and treated, and resulting in more effective treatment decisions that lead to improved outcomes. Transitioning your organization successfully to next generation healthcare depends on making accurate treatment decisions and managing care effectively. Let us show you how NantHealth can enabling that successful transition.

Learn About GPS Cancer™

Call Us:
1-844-MY-OMICS
(1-844-696-6427)

Email Us:
GPSCancer@NantHealth.com

Visit Us:
www.GPSCancer.com

Patrick Soon-Shiong, M.D., FRCS(C), FACS

Patrick Soon-Shiong, M.D., FRCS(C), FACS

Founder, Chief Executive Officer, and Chairman of the Board

“Our vision is to overcome traditional healthcare barriers and harness the power of innovation to achieve cutting edge advancements.”

Real Impact, Proven Results

%

Over 75% of oncology offices served nationwide

450,000 users on nationwide network

100 million lives nationwide

More than 30,000 medical devices connected

30 million monthly payer-provider transactions

2,000 hospitals use our solutions

60 Minutes: Disrupting the World of Cancer with Dr. Soon-Shiong

60 Minutes Overtime: Dr. Patrick Soon-Shiong, Shaking up Cancer

Stay Connected

FALSE REPORTING

While it is not befitting for us to dignify false reporting or be distracted by false claims, both an online health trade publication and an online political publication, published articles containing numerous inaccuracies. Letters we wrote to these publications, pointing out those inaccuracies, are posted on NantHealth’s website. As just one example:

The reporter stated, that NantWorks purchased the Jefferson property from the foundation for $6 million. That statement is false. What is worse, the reporter had the facts before he published the article, that NantWorks in fact paid $15.5M. Yet he published a false statement of apparent self-dealing by NantWorks by stating a fabricated amount of $6M.

The written statement the reporter sent to Dr. Soon-Shiong in his interview before the story published demonstrated this fact. He wrote: “According to our review of your form 990s, the NantHealth Foundation sold nearly $15.5 million in assets to NantWorks, LLC,” which clearly demonstrates that he knew he was publishing a false number. Thus, the reporter was well aware and understood the false and defamatory implication of what he wrote.

The reporter’s assertion that NantWorks paid $6M is also belied as can be seen in the foundations publicly viewable tax returns. The foundation sold the 9920 Jefferson property in May, 2012 to NantWorks for $15,450,000. The price was based on two appraisals, which came in within 99% of each other, by unaffiliated and well-regarded real estate appraisal firms. Upon advice of counsel, the disinterested foundation directors decided to sell the real estate to NantWorks, at the median price between the two appraisals. Dr. Soon-Shiong did not participate in the directors’ decision. Rather, he disclosed his conflict to the foundation’s board and recused himself from the meeting before the vote.

We demanded a retraction and correction but so far, the editors declined.

Patrick Soon-Shiong MD, FRCS(C), FACS
Chairman and CEO
NantWorks